Heart Failure (Acute Decompensation)
Heart failure is a clinical syndrome caused by a structural and/or functional cardiac disorder that leads to symptoms and signs of impaired cardiac filling and/or reduced cardiac output. [1] Management of acute decompensated heart failure focuses on treating congestion and precipitating causes, with diuretic therapy as the key immediate intervention when fluid overload is present. [1]
Cardiogenic Shock
Cardiogenic shock is an acute state of inadequate systemic perfusion due to cardiac pump failure, typically accompanied by hypotension or other evidence of hypoperfusion. [1] In cardiogenic shock, end-organ hypoperfusion occurs despite efforts to maintain systemic perfusion, and treatment prioritizes rapid hemodynamic support and definitive cause management. [1]
Key Differences in Clinical Presentation and Hemodynamics
Acute decompensated heart failure can occur with congestion and may be accompanied by variable blood pressure, whereas cardiogenic shock requires hemodynamic evidence of shock physiology with hypoperfusion and severe cardiac failure. [1] In the 2022 AHA/ACC/HFSA guideline, shock clinical criteria include systolic blood pressure <90 mm Hg for >30 minutes (or mean BP <60 mm Hg for >30 minutes or need for vasopressors to maintain SBP ≥90 mm Hg or MAP ≥60 mm Hg), with hypoperfusion defined by criteria such as decreased mentation, cold extremities, urine output <30 mL/h, and lactate >2 mmol/L. [1] In the same guideline, shock hemodynamic criteria include SBP <90 mm Hg or mean BP <60 mm Hg with cardiac index <2.2 L/min/m2 and pulmonary capillary wedge pressure >15 mm Hg. [1]
Treatment Strategy for Acute Decompensated Heart Failure (Without Shock)
Intravenous loop diuretics are recommended for patients admitted with significant fluid overload to improve symptoms and reduce morbidity. [1] If diuresis is inadequate to relieve congestion, diuretic therapy should be intensified using higher doses of intravenous loop diuretics or addition of a second diuretic. [1] In patients admitted with decompensated heart failure without systemic hypotension, intravenous nitroglycerin or nitroprusside may be used as an adjuvant to diuretic therapy for relief of dyspnea. [1]
Medication Strategy for Cardiogenic Shock
In cardiogenic shock, intravenous inotropic support should be used to maintain systemic perfusion and preserve end-organ performance. [1] Intravenous inotropic and vasopressor agents used in heart failure and shock contexts include dobutamine and milrinone as inotropes and norepinephrine, epinephrine, and dopamine as adrenergic support options. [1] Long-term continuous intravenous inotropic therapy is potentially harmful in heart failure and is reserved for appropriate bridge or palliative indications rather than chronic management. [1]
Temporary Mechanical Circulatory Support and System-Level Care in Cardiogenic Shock
Temporary mechanical circulatory support (MCS) is reasonable when end-organ function cannot be maintained by pharmacologic means to support cardiac function. [1] Management by a multidisciplinary team experienced in shock is considered reasonable. [1] Placement of a pulmonary artery line may be considered to define hemodynamic subsets and appropriate management strategies in cardiogenic shock presentations. [1] For patients not rapidly responding to initial shock measures, triage to centers able to provide temporary MCS may be considered to optimize management. [1]
Initiation Thresholds and Diagnostic Anchors for Cardiogenic Shock
Cardiogenic shock diagnosis in the 2022 AHA/ACC/HFSA guideline requires at least one clinical shock criterion (e.g., SBP <90 mm Hg for >30 minutes or vasopressor requirement to maintain SBP ≥90 mm Hg) plus hemodynamic criteria such as cardiac index <2.0 L/min/m2 and SBP <90 mm Hg. [1] In clinical practice aligned with guideline criteria, early identification of these thresholds supports prompt initiation of inotropic support and consideration of temporary MCS when pharmacologic support is insufficient. [1]
Common Pitfalls to Avoid
Diuretic-based treatment alone is not appropriate for cardiogenic shock when end-organ hypoperfusion persists and systemic perfusion requires inotropic and/or vasopressor support. [1] Nitroglycerin or nitroprusside should not be used as an adjuvant for decompensated heart failure when systemic hypotension is present. [1] Long-term continuous intravenous inotropic therapy should not be used for heart failure outside bridge-to-advanced-therapy or palliative contexts. [1]
Targets and Goals of Therapy by Syndrome
Acute decompensated heart failure therapy targets relief of congestion and resolution of clinical evidence of fluid overload to improve symptoms and reduce rehospitalization risk. [1] Cardiogenic shock therapy targets maintenance of systemic perfusion and preservation of end-organ performance through inotropic support and escalation to temporary MCS when needed. [1]